Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer

G. Bandara, G. M. Mueller, J. Galea-Lauri, M. H. Tindal, H. I. Georgescu, M. K. Suchanek, G. L. Hung, J. C. Glorioso, P. D. Robbins, Christopher H Evans

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

Gene therapy offers a radical different approach to the treatment of arthritis. Here we have demonstrated that two marker genes (lacZ and neo) and cDNA coding for a potentially therapeutic protein (human interleukin 1- receptor-antagonist protein; IRAP or IL-1ra) can be delivered, by ex vivo techniques, to the synovial lining of joints; intraarticular expression of IRAP inhibited intraarticular responses to interleukin 1. To achieve this, lapine synoviocytes were first transduced in culture by retroviral infection. The genetically modified synovial cells were then transplanted by intraarticular injection into the knee joints of rabbits, where they efficiently colonized the synovium. Assay of joint lavages confirmed the in vivo expression of biologically active human IRAP. With allografted cells, IRAP expression was lost by 12 days after transfer. In contrast, autografted synoviocytes continued to express IRAP for ≃5 weeks. Knee joints expressing human IRAP were protected from the leukocytosis that otherwise follows the intraarticular injection of recombinant human interleukin 1β. Thus, we report the intraarticular expression and activity of a potentially therapeutic protein by gene-transfer technology; these experiments demonstrate the feasibility of treating arthritis and other joint disorders with gene therapy.

Original languageEnglish (US)
Pages (from-to)10764-10768
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume90
Issue number22
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Intra-Articular Injections
Joints
Knee Joint
Interleukin-1
Genetic Therapy
Arthritis
Genes
Technology Transfer
Lac Operon
Synovial Membrane
Therapeutic Irrigation
Leukocytosis
Proteins
Therapeutics
Complementary DNA
Rabbits
Infection
Synoviocytes

Keywords

  • arthritis
  • cell transplantation
  • gene therapy

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer. / Bandara, G.; Mueller, G. M.; Galea-Lauri, J.; Tindal, M. H.; Georgescu, H. I.; Suchanek, M. K.; Hung, G. L.; Glorioso, J. C.; Robbins, P. D.; Evans, Christopher H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, No. 22, 1993, p. 10764-10768.

Research output: Contribution to journalArticle

Bandara, G. ; Mueller, G. M. ; Galea-Lauri, J. ; Tindal, M. H. ; Georgescu, H. I. ; Suchanek, M. K. ; Hung, G. L. ; Glorioso, J. C. ; Robbins, P. D. ; Evans, Christopher H. / Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer. In: Proceedings of the National Academy of Sciences of the United States of America. 1993 ; Vol. 90, No. 22. pp. 10764-10768.
@article{4efe5c861c474f789b734ef94081f137,
title = "Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer",
abstract = "Gene therapy offers a radical different approach to the treatment of arthritis. Here we have demonstrated that two marker genes (lacZ and neo) and cDNA coding for a potentially therapeutic protein (human interleukin 1- receptor-antagonist protein; IRAP or IL-1ra) can be delivered, by ex vivo techniques, to the synovial lining of joints; intraarticular expression of IRAP inhibited intraarticular responses to interleukin 1. To achieve this, lapine synoviocytes were first transduced in culture by retroviral infection. The genetically modified synovial cells were then transplanted by intraarticular injection into the knee joints of rabbits, where they efficiently colonized the synovium. Assay of joint lavages confirmed the in vivo expression of biologically active human IRAP. With allografted cells, IRAP expression was lost by 12 days after transfer. In contrast, autografted synoviocytes continued to express IRAP for ≃5 weeks. Knee joints expressing human IRAP were protected from the leukocytosis that otherwise follows the intraarticular injection of recombinant human interleukin 1β. Thus, we report the intraarticular expression and activity of a potentially therapeutic protein by gene-transfer technology; these experiments demonstrate the feasibility of treating arthritis and other joint disorders with gene therapy.",
keywords = "arthritis, cell transplantation, gene therapy",
author = "G. Bandara and Mueller, {G. M.} and J. Galea-Lauri and Tindal, {M. H.} and Georgescu, {H. I.} and Suchanek, {M. K.} and Hung, {G. L.} and Glorioso, {J. C.} and Robbins, {P. D.} and Evans, {Christopher H}",
year = "1993",
doi = "10.1073/pnas.90.22.10764",
language = "English (US)",
volume = "90",
pages = "10764--10768",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "22",

}

TY - JOUR

T1 - Intraarticular expression of biologically active interleukin 1-receptor- antagonist protein by ex vivo gene transfer

AU - Bandara, G.

AU - Mueller, G. M.

AU - Galea-Lauri, J.

AU - Tindal, M. H.

AU - Georgescu, H. I.

AU - Suchanek, M. K.

AU - Hung, G. L.

AU - Glorioso, J. C.

AU - Robbins, P. D.

AU - Evans, Christopher H

PY - 1993

Y1 - 1993

N2 - Gene therapy offers a radical different approach to the treatment of arthritis. Here we have demonstrated that two marker genes (lacZ and neo) and cDNA coding for a potentially therapeutic protein (human interleukin 1- receptor-antagonist protein; IRAP or IL-1ra) can be delivered, by ex vivo techniques, to the synovial lining of joints; intraarticular expression of IRAP inhibited intraarticular responses to interleukin 1. To achieve this, lapine synoviocytes were first transduced in culture by retroviral infection. The genetically modified synovial cells were then transplanted by intraarticular injection into the knee joints of rabbits, where they efficiently colonized the synovium. Assay of joint lavages confirmed the in vivo expression of biologically active human IRAP. With allografted cells, IRAP expression was lost by 12 days after transfer. In contrast, autografted synoviocytes continued to express IRAP for ≃5 weeks. Knee joints expressing human IRAP were protected from the leukocytosis that otherwise follows the intraarticular injection of recombinant human interleukin 1β. Thus, we report the intraarticular expression and activity of a potentially therapeutic protein by gene-transfer technology; these experiments demonstrate the feasibility of treating arthritis and other joint disorders with gene therapy.

AB - Gene therapy offers a radical different approach to the treatment of arthritis. Here we have demonstrated that two marker genes (lacZ and neo) and cDNA coding for a potentially therapeutic protein (human interleukin 1- receptor-antagonist protein; IRAP or IL-1ra) can be delivered, by ex vivo techniques, to the synovial lining of joints; intraarticular expression of IRAP inhibited intraarticular responses to interleukin 1. To achieve this, lapine synoviocytes were first transduced in culture by retroviral infection. The genetically modified synovial cells were then transplanted by intraarticular injection into the knee joints of rabbits, where they efficiently colonized the synovium. Assay of joint lavages confirmed the in vivo expression of biologically active human IRAP. With allografted cells, IRAP expression was lost by 12 days after transfer. In contrast, autografted synoviocytes continued to express IRAP for ≃5 weeks. Knee joints expressing human IRAP were protected from the leukocytosis that otherwise follows the intraarticular injection of recombinant human interleukin 1β. Thus, we report the intraarticular expression and activity of a potentially therapeutic protein by gene-transfer technology; these experiments demonstrate the feasibility of treating arthritis and other joint disorders with gene therapy.

KW - arthritis

KW - cell transplantation

KW - gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0027435633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027435633&partnerID=8YFLogxK

U2 - 10.1073/pnas.90.22.10764

DO - 10.1073/pnas.90.22.10764

M3 - Article

C2 - 8248169

AN - SCOPUS:0027435633

VL - 90

SP - 10764

EP - 10768

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 22

ER -